首页> 外文期刊>BMC Immunology >Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands
【24h】

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands

机译:协同的toll样受体配体增强了编码树突状细胞靶向抗原的DNA疫苗的引发效力

获取原文
           

摘要

Background Targeting of protein antigens to dendritic cells (DC) via the DEC205 receptor enhances presentation of antigen-derived peptides on MHC-I and MHC-II molecules and, in the presence of costimulatory signals, antigen-specific immune responses. The immunogenicity and efficacy of DNA vaccination can also be enhanced by fusing the encoded antigen to single chain antibodies directed against DEC205. To further improve this strategy, we evaluated different toll-like receptor ligands (TLR) and CD40 ligands (CD40L) as adjuvants for DNA vaccines encoding a DEC205-single-chain antibody fused to the ovalbumin model antigen or HIV-1 Gag and assessed the priming efficacy of DNA in a DNA prime adenoviral vector boost immunization regimen. Results Mice were primed with the adjuvanted DEC-205 targeted DNA vaccines and boosted with adenoviral vectors encoding the same antigens. CD8+ T cell responses were determined after the adenoviral booster immunization, to determine how well the different DNA immunization regimens prime for the adenoviral boost. In the absence of adjuvants, targeting of DNA-encoded ovalbumin to DCs suppressed CD8+ T-cell responses after the adenoviral booster immunization. CD8+ T-cell responses to the DEC205 targeted DNA vaccines increased only slightly by adding either the TLR-9 ligand CpG, the TLR-3 ligand Poly I:C, or CD40 ligand expression plasmids. However, the combination of both TLR-ligands led to a strong enhancement of CD8+ T-cell responses compared to a non-targeted DNA vaccine. This finding was confirmed using HIV Gag as antigen. Conclusion Although DNA prime adenoviral vector boost immunizations belong to the strongest inducers of cytotoxic T cell responses in different animal models and humans, the CD8+ T cell responses can be further improved by targeting the DNA encoded antigen to DEC205 in the presence of synergistic TLR ligands CpG and Poly I:C.
机译:背景技术通过DEC205受体将蛋白抗原靶向树突状细胞(DC)可增强MHC-I和MHC-II分子上抗原衍生肽的呈递,并在存在共刺激信号的情况下增强抗原特异性免疫应答。通过将编码的抗原与针对DEC205的单链抗体融合,也可以提高DNA疫苗的免疫原性和效力。为了进一步改善此策略,我们评估了不同的收费型受体配体(TLR)和CD40配体(CD40L)作为编码与卵白蛋白模型抗原或HIV-1 Gag融合的DEC205单链抗体的DNA疫苗的佐剂,并评估了DNA初免腺病毒载体加强免疫方案中DNA的初免效力。结果小鼠用DEC-205靶向DNA佐剂疫苗接种,并用编码相同抗原的腺病毒载体加强免疫。在腺病毒加强免疫后确定CD8 + T细胞应答,以确定不同的DNA免疫方案对腺病毒加强免疫的准备程度。在没有佐剂的情况下,腺病毒加强免疫后,将DNA编码的卵清蛋白靶向DCs可抑制CD8 + T细胞应答。通过添加TLR-9配体CpG,TLR-3配体Poly I:C或CD40配体表达质粒,对DEC205靶向DNA疫苗的CD8 T细胞应答仅略有增加。但是,与非靶向DNA疫苗相比,这两种TLR配体的结合导致CD8 + T细胞应答的强烈增强。使用HIV Gag作为抗原证实了这一发现。结论尽管在不同的动物模型和人类中,DNA初始腺病毒载体加强免疫是最强的细胞毒性T细胞反应的诱导剂,但通过将DNA编码的抗原靶向DEC205,可以进一步改善CD8 + T细胞反应在协同TLR配体CpG和Poly I:C的存在下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号